TC BIOPHARM



TECHNOLOGY OVERVIEW

March 2014

Dr Michael D Leek (Chief Executive)

BACKGROUND:

- **TC BioPharm aims to build a sustainable drug development product pipeline, with multiple opportunities for value uplift and liquidity which include:**

  - collaborative partnerships
  - outward licensing
  - direct sales
  - IPO and/or acquisition

- **Incorporated late 2013, founding team have extensive, proven commercial capability, having previously taken over 10 therapies to clinic, raising over £20m in equity/grant finance.**

- **The Company has secured £1.4m funding to date and is seeking an additional cash to enable clinical studies.**



BACKGROUND:

- **The lead product is a novel anti-cancer immunotherapy with potential to treat ALL tumour types.**

- **Core technology is based on proprietary methods for delivery of therapeutic autologous γδ T lymphocytes to the patient.**

- **Proposed UK in-man trials will treat myeloma patients and individuals with melanoma (scheduled Q1, 2015).**



THE PRODUCT - γδ T LYMPHOCYTES:

- γδ T lymphocytes are known to destroy cancer cells…
- Patients own γδ T lymphocytes expanded in tissue culture
- Proprietary 2.4 litre closed (bag) expansion system
- Patient given six doses of $1x10^7$ – $1x10^9$ viable γδ T lymphocytes
- Stratified approach based on unique (miRNA) biomarkers

TC BIOPHARM



WHAT ARE γδ T LYMPHOCYTES ?

- **Present as 5% of circulating white blood cells**
- **Cytotoxic to cancer cells…**



(1) A human γδ T lymphocyte (T) identifies and (2) scans the surface of a cancer cell (C). On contact with the cancer cell (3) the T lymphocyte releases perforin granules (stained red) into the cancer cell, rupturing it's membrane destroying the cancer cell (4).
Adapted from - Enc Life Sci, Jul-2007

TC BIOPHARM



THE BUSINESS:

- **Commercial competencies include:**
  - **new product development**
  - **GMP manufacture of MHRA/FDA regulated therapies**
  - **UK/EU/US regulatory affairs**
  - **UK/EU/US clinical trials to market authorisation**

- **The business objectives are to:**
  - **launch a novel cancer therapy within 5 years**
  - **build a sustainable 'biologics' product pipeline**
  - **become a major force in personalised/stratified medicine**
  - **generate significant uplift in Company valuation**
  - **provide an exit for investors within 4-6 years**

TC BIOPHARM



USP's and DIFFERENTATION:

- First mover advantage with a GMP compliant γδ T cell therapy
- γδ T lymphocytes have a unique biological 'mode of action'
- Single product is applicable to a wide range of cancer types
- Attractive to Pharma (as part of a stratified medicine pipeline)
- Barriers to entry include patents and GMP infrastructure

TC BIOPHARM



CLINICAL and REGULATORY:

- MHRA Scientific Advice meeting held Q4, 2013
- No additional pre-clinical safety data required
- Endorsed the stratified approach to recruitment and treatment
- Classified trial design as ‘adaptive’
- Conventional phase I/II/III not applicable
- QP and MHRA review of GMP cleanroom design ongoing

TC BIOPHARM

CAPABILITY and INFRASTRUCTURE (I):

- **Founding team:**
  - **Dr Michael Leek (commercial cell therapy, fundraising)**
  - **Mr Kuni Suzuki (CEO - Medinet)**
  - **Dr Ryuji Maekawa (Head of R&D Division, GM of Medinet Med Inst)**
  - **Mrs Angela Scott (GMP manufacture)**

- **Clinical Advisory Board:**
  - **Prof Jeff Evans (CR-UK, Glasgow)**
  - **Prof Christian Ottensmeier (CR-UK, Southampton)**
  - **Prof Paul Shiels (Glasgow University)**

- **GMP compliant facility based at Eurocentral (below)**

(Total = 7,500 sq ft; initial build = 5,000 sq ft ; cleanrooms = 500 sq ft)

TC BIOPHARM

CAPABILITY and INFRASTRUCTURE (II):



TC BIOPHARM

SUMMARY:

- Highly innovative cancer immunotherapy
- Clear market demand and route to revenue
- Measurable annual uplift in value
- Planned exit and liquidity within 5 years
- Places UK at forefront of therapeutic stratified medicine
- Potential to significantly improve patient QoL

TC BIOPHARM



TC
BIOPHARM